Prüfung der Verwendung der Prüfpräparate Atezolizumab und/oder Bevacizumab mit oder ohne Standard-Chemotherapie in der Zweitlinienbehandlung von Kopf- und Halskrebs im fortgeschrittenen Stadium
Eine Phase-II/III-Studie zu Chemotherapie + Cetuximab vs. Chemotherapie + Bevacizumab vs. Atezolizumab + Bevacizumab nach Progression bei Immun-Checkpoint-Hemmung bei rezidivierendem/metastasiertem Kopf- und Halskrebs
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
- Rezidivierendes Kopf-Hals-Plattenepithelkarzinom
- Wiederkehrendes hypopharyngeales Plattenepithelkarzinom
- Rezidivierendes Plattenepithelkarzinom des Larynx
- Metastasierendes Kopf-Hals-Plattenepithelkarzinom
- HPV-vermitteltes (p16-positiv) Oropharynxkarzinom im klinischen Stadium IV AJCC v8
- Stadium IV Hypopharynxkarzinom AJCC v8
- Kehlkopfkrebs Stadium IV AJCC v8
- Lippen- und Mundhöhlenkrebs im Stadium IV AJCC v8
- Stadium IV Oropharynxkarzinom (p16-negativ) AJCC v8
- Metastasierendes hypopharyngeales Plattenepithelkarzinom
- Metastasierendes Plattenepithelkarzinom des Larynx
- Metastasierendes Lippen- und Mundhöhlenkarzinom
- Metastasierendes Plattenepithelkarzinom der Nasenhöhle
- Metastasierendes Plattenepithelkarzinom des Nasopharynx
- Metastasierendes Pharynx-Plattenepithelkarzinom
- Metastasierendes sinonasales Plattenepithelkarzinom
- Rezidivierendes Plattenepithelkarzinom der Lippen und der Mundhöhle
- Rezidivierendes Plattenepithelkarzinom des Nasopharynx
- Rezidivierendes Pharynx-Plattenepithelkarzinom
- Rezidivierendes sinonasales Plattenepithelkarzinom
- Stadium IV Nasopharynxkarzinom AJCC v8
- Stadium IV Nasennebenhöhlenkrebs AJCC v8
- Stufe IV Kopf und Nacken Hautkarzinom AJCC V8
Intervention / Behandlung
Intervention / Behandlung
- Arzneimittel: Carboplatin
- Biologisch: Bevacizumab
- Arzneimittel: Cisplatin
- Arzneimittel: Docetaxel
- Verfahren: Biospecimen Collection
- Verfahren: Magnetic Resonance Imaging
- Verfahren: Echocardiography Test
- Verfahren: Computed Tomography
- Verfahren: Positron Emission Tomography
- Biologisch: Atezolizumab
- Biologisch: Cetuximab
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.
PHASE II: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening.
ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
PHASE III: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Dublin, California, Vereinigte Staaten, 94568
- Epic Care-Dublin
-
Emeryville, California, Vereinigte Staaten, 94608
- Epic Care Partners in Cancer Care
-
Irvine, California, Vereinigte Staaten, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Martinez, California, Vereinigte Staaten, 94553-3156
- Contra Costa Regional Medical Center
-
Orange, California, Vereinigte Staaten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Vereinigte Staaten, 94304
- VA Palo Alto Health Care System
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford Cancer Institute Palo Alto
-
-
Connecticut
-
Derby, Connecticut, Vereinigte Staaten, 06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield, Connecticut, Vereinigte Staaten, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury, Connecticut, Vereinigte Staaten, 06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Vereinigte Staaten, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Vereinigte Staaten, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Vereinigte Staaten, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
North Haven, Connecticut, Vereinigte Staaten, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Orange, Connecticut, Vereinigte Staaten, 06477
- Smilow Cancer Hospital-Orange Care Center
-
Stamford, Connecticut, Vereinigte Staaten, 06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington, Connecticut, Vereinigte Staaten, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Vereinigte Staaten, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury, Connecticut, Vereinigte Staaten, 06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford, Connecticut, Vereinigte Staaten, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Vereinigte Staaten, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Coral Gables, Florida, Vereinigte Staaten, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Vereinigte Staaten, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Broward Health Medical Center
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Vereinigte Staaten, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Vereinigte Staaten, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Vereinigte Staaten, 60504
- Rush-Copley Medical Center
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- John H Stroger Jr Hospital of Cook County
-
Danville, Illinois, Vereinigte Staaten, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Carle Physician Group-Effingham
-
Harvey, Illinois, Vereinigte Staaten, 60426
- Ingalls Memorial Hospital
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Vereinigte Staaten, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- University of Chicago Medicine-Orland Park
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Carle Cancer Center
-
Yorkville, Illinois, Vereinigte Staaten, 60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Vereinigte Staaten, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Vereinigte Staaten, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone, Iowa, Vereinigte Staaten, 50036
- McFarland Clinic - Boone
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Vereinigte Staaten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Vereinigte Staaten, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Vereinigte Staaten, 50158
- McFarland Clinic - Marshalltown
-
Waukee, Iowa, Vereinigte Staaten, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- University Medical Center New Orleans
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Vereinigte Staaten, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland/Greenebaum Cancer Center
-
Cumberland, Maryland, Vereinigte Staaten, 21502
- UPMC Western Maryland
-
-
Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- UMass Memorial Medical Center - University Campus
-
-
Minnesota
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Saint Francis Medical Center
-
St Louis, Missouri, Vereinigte Staaten, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Benefis Sletten Cancer Institute
-
Missoula, Montana, Vereinigte Staaten, 59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Vereinigte Staaten, 88011
- Memorial Medical Center-Las Cruces
-
-
North Carolina
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Vereinigte Staaten, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Vereinigte Staaten, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Kettering Medical Center
-
Steubenville, Ohio, Vereinigte Staaten, 43952
- Trinity's Tony Teramana Cancer Center
-
Toledo, Ohio, Vereinigte Staaten, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Vereinigte Staaten, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, Vereinigte Staaten, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Vereinigte Staaten, 15009
- UPMC-Heritage Valley Health System Beaver
-
Butler, Pennsylvania, Vereinigte Staaten, 16001
- UPMC Hillman Cancer Center at Butler Health System
-
Camp Hill, Pennsylvania, Vereinigte Staaten, 17011
- UPMC Camp Hill
-
Carlisle, Pennsylvania, Vereinigte Staaten, 17015
- Carlisle Regional Cancer Center
-
Cranberry Township, Pennsylvania, Vereinigte Staaten, 16066
- UPMC Hillman Cancer Center - Passavant - Cranberry
-
Erie, Pennsylvania, Vereinigte Staaten, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Vereinigte Staaten, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Vereinigte Staaten, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville, Pennsylvania, Vereinigte Staaten, 16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Harrisburg, Pennsylvania, Vereinigte Staaten, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Indiana, Pennsylvania, Vereinigte Staaten, 15701
- IRMC Cancer Center
-
Johnstown, Pennsylvania, Vereinigte Staaten, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, Vereinigte Staaten, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Vereinigte Staaten, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Vereinigte Staaten, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Mount Pleasant, Pennsylvania, Vereinigte Staaten, 15666
- UPMC Hillman Cancer Center - Part of Frick Hospital
-
N. Huntingdon, Pennsylvania, Vereinigte Staaten, 15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
Natrona Heights, Pennsylvania, Vereinigte Staaten, 15065
- UPMC Cancer Center-Natrona Heights
-
New Castle, Pennsylvania, Vereinigte Staaten, 16105
- UPMC Hillman Cancer Center - New Castle
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15219
- UPMC-Mercy Hospital
-
Seneca, Pennsylvania, Vereinigte Staaten, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Vereinigte Staaten, 15401
- UPMC Cancer Center-Uniontown
-
Washington, Pennsylvania, Vereinigte Staaten, 15301
- UPMC Cancer Center-Washington
-
West Mifflin, Pennsylvania, Vereinigte Staaten, 15122
- UPMC West Mifflin-Cancer Center Jefferson
-
Williamsport, Pennsylvania, Vereinigte Staaten, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Vereinigte Staaten, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Vereinigte Staaten, 17408
- UPMC Memorial
-
-
Rhode Island
-
Westerly, Rhode Island, Vereinigte Staaten, 02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Dakota
-
Rapid City, South Dakota, Vereinigte Staaten, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Vereinigte Staaten, 37932
- Covenant Health Cancer Centers - West
-
Lenoir City, Tennessee, Vereinigte Staaten, 37772
- Covenant Health Oncology Group - Lenoir City
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University/Ingram Cancer Center
-
Oak Ridge, Tennessee, Vereinigte Staaten, 37830
- Covenant Health Oncology Group - Oak Ridge
-
-
Vermont
-
Saint Johnsbury, Vermont, Vereinigte Staaten, 05819
- Dartmouth Cancer Center - North
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- UW Cancer Center at ProHealth Care
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma [SCC] of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin)
-
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible
-
Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization.
- NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study
-
Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial
-
Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration
-
Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy:
- Prior carotid bleeding,
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies,
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies,
- Any prior history of bleeding related to the current head and neck cancer,
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization
-
Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism
-
Patient must not have a history of coagulopathy or hemorrhagic disorders
-
Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed)
-
Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents [e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function
-
Patient must have PD-L1 expression >= 1% by CPS in the tumor and/or immune cells
- NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility
-
Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis
-
Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy
-
Patient must not have a history of solid organ transplantation or stem-cell transplant
-
Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions
-
Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded
-
Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
- NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria)
-
Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization)
-
Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX [registered trademark])
-
Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization
-
Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period
-
Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment
-
Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
-
Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo CT scan
Andere Namen:
Undergo PET scan
Andere Namen:
Given IV
Andere Namen:
|
|
Experimental: Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo CT scan
Andere Namen:
Undergo PET scan
Andere Namen:
|
|
Experimental: Phase II, Arm C (Bevacizumab, Atezolizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo CT scan
Andere Namen:
Undergo PET scan
Andere Namen:
Given IV
Andere Namen:
|
|
Experimental: Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo CT scan
Andere Namen:
Undergo PET scan
Andere Namen:
Given IV
Andere Namen:
|
|
Experimental: Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)
Patients receive treatment as in Arm B or C above based on results of the Phase II trial. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo CT scan
Andere Namen:
Undergo PET scan
Andere Namen:
Given IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progressionsfreies Überleben (PFS) (Phase II)
Zeitfenster: Zeit vom Behandlungsbeginn bis zum Fortschreiten der Krankheit oder Tod, bewertet bis zu 5 Jahre nach Randomisierung
|
Zeit vom Behandlungsbeginn bis zum Fortschreiten der Krankheit oder Tod, bewertet bis zu 5 Jahre nach Randomisierung
|
|
|
Overall survival (OS) (Phase III)
Zeitfenster: Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Will be compared using a stratified log rank test. |
Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Häufigkeit unerwünschter Ereignisse (Phase III)
Zeitfenster: Bis zu 30 Tage nach Abschluss der Behandlung
|
Bis zu 30 Tage nach Abschluss der Behandlung
|
|
|
OS in the subset of patients with high PD-L1 expression (Phase III)
Zeitfenster: Up to 5 years from randomization
|
The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model. |
Up to 5 years from randomization
|
|
Correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers
Zeitfenster: Up to 5 years from randomization
|
The two-sample t-test will be used to compare the difference of baseline 18F -FDG PET /CT imaging biomarkers (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) between low and high expression of PD-L1. |
Up to 5 years from randomization
|
|
Prediction of treatment response
Zeitfenster: Baseline up to 12 weeks
|
Determined by 18FDG-PET/CT and CT neck imaging biomarkers. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post-treatment, PFS, and OS Logistic regression model will be fit to assess the association of the 18F -FDG PET /CT imaging biomarkers (e.g., SUVmax, MTV, TLG, tumor heterogeneity, tumor volume) with binary treatment response at 9-12 weeks post treatment. Cox proportional hazards models will be fit to assess the association of 18F -FDG PET /CT imaging biomarkers with time-to-event outcomes (PFS or OS). |
Baseline up to 12 weeks
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression
Zeitfenster: Up to 5 years from randomization
|
The imaging textural features from radiomics analysis will be associated with the dichotomized PD-L1 expressions. First, proper transformation will be applied to the textural features as needed to address the distribution skewness. Second, Pearson or Spearman rank correlations will be calculated between all pairs of textural features to identify highly correlated features. Third, to address overfitting and high collinearity, machine learning techniques (e.g., LASSO or XGBoost) will be employed for feature selection during the association analysis with PD-L1 expressions. |
Up to 5 years from randomization
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Aarti Bhatia, ECOG-ACRIN Cancer Research Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Mundkrankheiten
- Stomatognathe Erkrankungen
- Neubildungen nach Standort
- Neubildungen
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Kopf-Hals-Neubildungen
- Neubildungen, Drüsen und Epithelien
- Neubildungen der Atemwege
- Otorhinolaryngologische Erkrankungen
- Rachenneoplasmen
- Otorhinolaryngologische Neubildungen
- Nasopharyngeale Erkrankungen
- Rachenkrankheiten
- Karzinom, Plattenepithel
- Kehlkopferkrankungen
- Nasopharyngeale Neoplasmen
- Nasopharynxkarzinom
- Plattenepithelkarzinom von Kopf und Hals
- Karzinom
- Larynxneoplasmen
- Neubildungen im Mund
- Oropharyngeale Neubildungen
- Hypopharyngeale Neubildungen
- Lymphe interstitielle Lungenentzündung
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Koordinationskomplexe
- Taxoid
- Cyclodececane
- Diterpene
- Elemente
- Metalle
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Metalle, schwer
- Immunglobulinisotypen
- Sulfide
- Anionen
- Ionen
- Elektrolyte
- Schwefelwasserstoff
- Platinverbindungen
- Übergangselemente
- Docetaxel
- Bevacizumab
- Cetuximab
- Carboplatin
- Immunglobulin G
- Cisplatin
- 1,2-Diaminocyclohexanplatin-II-Citrat
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Disulfide
- Platin
- Atezolizumab
- (225) AC-DOTA-C (RGDYK)
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2021-10021
- U10CA180820 (US NIH Stipendium/Vertrag)
- NCI-2021-10021 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- EA3202 (Andere Kennung: CTEP)
- EA3202 (Andere Kennung: ECOG-ACRIN Cancer Research Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .